Genital Herpes Clinical Trial
Official title:
Serologic Assays for the Diagnosis of Herpes Simplex Virus Type 2: Development of Testing Strategies
The purposes of this study are:
- To determine the accuracy of commercially available serologic assays in diagnosing
patients with herpes simplex virus type 2 (HSV-2);
- To assess the sensitivity and specificity of the commerical assays using HSV-2 western
blot as the "gold standard" in a diverse patient population;
- To develop testing strategies and recommendations for screening asymptomatic
populations for HSV-2.
The purposes of this study are:
- To determine the accuracy of commercially available serologic assays in diagnosing
patients with herpes simplex virus type 2 (HSV-2);
- To assess the sensitivity and specificity of the commerical assays using HSV-2 western
blot as the "gold standard" in a diverse patient population;
- To develop testing strategies and recommendations for screening asymptomatic
populations for HSV-2.
We will evaluate the assays in diverse populations:
1. STD clinic population
2. Men who have sex with men, with high prevalence of HIV infection
3. Pregnant women
The study will inform the development of testing strategies:
1. Combine commercial tests to optimize positive predict value (PPV) and negative predict
value (NPV)
2. Increase cutoff values to increase PPV
3. Understand factors associated with false positive results that may include HSV-1
infection, pregnancy status, HIV infection, and age/race etc.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06033261 -
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
|
Phase 1/Phase 2 | |
Completed |
NCT01132729 -
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions
|
N/A | |
Completed |
NCT01132716 -
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions
|
N/A | |
Completed |
NCT00362297 -
Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
|
Phase 4 | |
Completed |
NCT03831165 -
Melatonin Effects on Genital Herpes in Brazilian Women
|
Phase 4 | |
Terminated |
NCT01658826 -
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
|
Phase 2 | |
Completed |
NCT00262106 -
Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection
|
Phase 3 | |
Completed |
NCT01346475 -
Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
|
Phase 4 | |
Completed |
NCT01390805 -
Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)
|
N/A | |
Terminated |
NCT03146403 -
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
|
Phase 2 | |
Completed |
NCT03080961 -
The VIBLOK SAfety and perFormancE Trial
|
N/A | |
Completed |
NCT00231049 -
Trial Evaluating Safety, Tolerability and Immune Response of AG-707
|
Phase 1 | |
Completed |
NCT00306787 -
Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes
|
Phase 3 | |
Completed |
NCT00477334 -
Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients
|
Phase 4 | |
Completed |
NCT00495573 -
HSV-2 Shedding Resolution After Acyclovir Treatment
|
N/A | |
Not yet recruiting |
NCT03595995 -
A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621
|
Phase 2 | |
Completed |
NCT01281007 -
Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes
|
Phase 3 | |
Completed |
NCT00129818 -
A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding
|
Phase 4 | |
Completed |
NCT00808405 -
GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women
|
N/A | |
Terminated |
NCT00495716 -
Effect of HSV-2 Suppressive Therapy on Sexual Behavior
|
Phase 4 |